The area under the effect curve as an efficacy determinant for anti-infectives.
Journal
CPT: pharmacometrics & systems pharmacology
ISSN: 2163-8306
Titre abrégé: CPT Pharmacometrics Syst Pharmacol
Pays: United States
ID NLM: 101580011
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
revised:
11
04
2022
received:
01
12
2021
accepted:
26
04
2022
pubmed:
1
6
2022
medline:
19
8
2022
entrez:
31
5
2022
Statut:
ppublish
Résumé
Pharmacokinetic/pharmacodynamic (PK/PD) indices making use of area under the curve, maximum concentration, and the duration that in vivo drug concentration is maintained above a critical level are commonly applied to clinical dose prediction from animal efficacy experiments in the infectious disease arena. These indices make suboptimal use of the nonclinical data, and the prediction depends on the shape of the PK profiles in the animals, determined by the species-specific absorption, distribution, metabolism, and elimination properties, and the dosing regimen used in the efficacy experiments. Motivated by the principle that efficacy is driven by pharmacology, we conducted simulations using a generalized pathogen dynamic model, to assess the properties of an alternative efficacy predictor: the area under the effect curve (AUEC), computed using in vitro PD and in vivo PK. Across a wide range of hypothetical scenarios, the AUEC consistently showed regimen-independent strong correlation (R
Identifiants
pubmed: 35638366
doi: 10.1002/psp4.12811
pmc: PMC9381909
doi:
Substances chimiques
Anti-Bacterial Agents
0
Anti-Infective Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1029-1044Informations de copyright
© 2022 The Authors. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
Références
Antimicrob Agents Chemother. 2004 Feb;48(2):369-77
pubmed: 14742182
Nat Rev Microbiol. 2004 Apr;2(4):289-300
pubmed: 15031728
Clin Pharmacol Ther. 2020 Feb;107(2):324-332
pubmed: 31502248
Clin Infect Dis. 2007 Jan 1;44(1):79-86
pubmed: 17143821
PLoS Comput Biol. 2021 Mar 17;17(3):e1008785
pubmed: 33730053
Proc Natl Acad Sci U S A. 2017 Aug 15;114(33):8847-8852
pubmed: 28765371
Pharmacol Rev. 2013 Jun 26;65(3):1053-90
pubmed: 23803529
Antimicrob Agents Chemother. 2013 May;57(5):2343-51
pubmed: 23478962
Clin Pharmacol Ther. 2021 Dec;110(6):1426-1428
pubmed: 34555178
Microbiol Spectr. 2017 Jun;5(3):
pubmed: 28643624
Malar J. 2012 Aug 30;11:303
pubmed: 22931058
Clin Pharmacokinet. 2021 Jun;60(6):685-710
pubmed: 33674941
Clin Microbiol Rev. 2007 Jul;20(3):391-408, table of contents
pubmed: 17630331
CPT Pharmacometrics Syst Pharmacol. 2022 Aug;11(8):1029-1044
pubmed: 35638366
Clin Pharmacol Ther. 2021 Apr;109(4):867-891
pubmed: 33555032
AIDS. 2007 Jul;21 Suppl 4:S73-9
pubmed: 17620756
Antimicrob Agents Chemother. 2000 Dec;44(12):3414-24
pubmed: 11083649
Science. 1996 Mar 15;271(5255):1582-6
pubmed: 8599114
Pharm Res. 2016 May;33(5):1115-25
pubmed: 26786016
Antimicrob Agents Chemother. 2011 Oct;55(10):4619-30
pubmed: 21807983
J Antimicrob Chemother. 2018 Feb 1;73(2):437-447
pubmed: 29136155
Antimicrob Agents Chemother. 2013 Jan;57(1):508-16
pubmed: 23147722
Drug Discov Today. 2019 Feb;24(2):371-376
pubmed: 30448352
Nat Commun. 2018 Oct 1;9(1):4013
pubmed: 30275474